Literature DB >> 28397583

Immunohistochemistry Analysis of CD44, EGFR, and p16 in Oral Cavity and Oropharyngeal Squamous Cell Carcinoma.

Erin R Cohen1, Isildinha M Reis2,3, Carmen Gomez4, Lutecia Pereira2, Monika E Freiser1, Gia Hoosien1, Elizabeth J Franzmann1,2.   

Abstract

Objectives We analyze the relationship between CD44, epidermal growth factor receptor (EGFR), and p16 expression in oral cavity and oropharyngeal cancers in a diverse population. We also describe whether particular patterns of staining are associated with progression-free survival and overall survival. Study Design Prospective study, single-blind to pathologist and laboratory technologist. Setting Hospital based. Subjects and Methods Immunohistochemistry, comprising gross staining and cellular expression, was performed and interpreted in a blinded fashion on 24 lip/oral cavity and 40 oropharyngeal cancer specimens collected between 2007 and 2012 from participants of a larger study. Information on overall survival and progression-free survival was obtained from medical records. Results Nineteen cases were clinically p16 positive, 16 of which were oropharyngeal. Oral cavity lesions were more likely to exhibit strong CD44 membrane staining ( P = .0002). Strong CD44 membrane and strong EGFR membrane and/or cytoplasmic staining were more common in p16-negative cancers ( P = .006). Peripheral/mixed gross p16 staining pattern was associated with worse survival than the universal staining on univariate and multivariate analyses ( P = .006, P = .030). This held true when combining gross and cellular localization for p16. For CD44, universal gross staining demonstrated poorer overall survival compared with the peripheral/mixed group ( P = .039). CD44 peripheral/mixed group alone and when combined with universal p16 demonstrated the best survival on multivariate analysis ( P = .010). Conclusion In a diverse population, systematic analysis applying p16, CD44, and EGFR gross staining and cellular localization on immunohistochemistry demonstrates distinct patterns that may have prognostic potential exceeding current methods. Larger studies are warranted to investigate these findings further.

Entities:  

Keywords:  CD44; EGFR; head and neck malignancy; immunohistochemistry; p16; squamous cell carcinoma

Mesh:

Substances:

Year:  2017        PMID: 28397583     DOI: 10.1177/0194599817700371

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  5 in total

Review 1.  Dissecting the role of hyaluronan synthases in the tumor microenvironment.

Authors:  Alberto Passi; Davide Vigetti; Simone Buraschi; Renato V Iozzo
Journal:  FEBS J       Date:  2019-04-22       Impact factor: 5.542

2.  MicroRNA-15b-5p Predicts Locoregional Relapse in Head and Neck Carcinoma Patients Treated With Intensity-modulated Radiotherapy.

Authors:  Parwez Ahmad; Jiri Sana; Marek Slavik; Dominik Gurin; Lenka Radova; Natalia Anna Gablo; Tomas Kazda; Pavel Smilek; Zuzana Horakova; Bretislav Gal; Marketa Hermanova; Pavel Slampa; Ondrej Slaby
Journal:  Cancer Genomics Proteomics       Date:  2019 Mar-Apr       Impact factor: 4.069

3.  Post-Treatment HPV Surface Brushings and Risk of Relapse in Oropharyngeal Carcinoma.

Authors:  Barbara Kofler; Wegene Borena; Jozsef Dudas; Veronika Innerhofer; Daniel Dejaco; Teresa B Steinbichler; Gerlig Widmann; Dorothee von Laer; Herbert Riechelmann
Journal:  Cancers (Basel)       Date:  2020-04-25       Impact factor: 6.639

4.  Prognostic Worth of Epidermal Growth Factor Receptor (EGFR) in Patients with Head and Neck Tumors.

Authors:  Precious Barnes; F A Yeboah; Jinling Zhu; Roland Osei Saahene; Christian Obirikorang; Michael Buenor Adinortey; Benjamin Amoani; Foster Kyei; Patrick Akakpo; Yaw Asante Awuku
Journal:  J Cancer Epidemiol       Date:  2020-11-12

5.  High CD44 Immunoexpression Correlates with Poor Overall Survival: Assessing the Role of Cancer Stem Cell Markers in Oral Squamous Cell Carcinoma Patients from the High-Risk Population of Pakistan.

Authors:  Yumna Adnan; S M Adnan Ali; Hasnain A Farooqui; Hammad A Kayani; Romana Idrees; M Sohail Awan
Journal:  Int J Surg Oncol       Date:  2022-03-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.